Phase I study finished

We have completed phase I study with JAK kinase inhibitors.

The JAK family of non-receptor tyrosine kinases regulates the transduction of signals from cytokines and their receptors by activating STAT transcription factors and modulating the expression of STAT-dependent genes. Excessive activation of the JAK/STAT pathway has been confirmed in immune-related diseases, where JAK kinases participate in the induction and maintenance of inflammation. The development of therapy based on the inhibition of JAK family kinases has applications in many areas: oncology by inhibiting excessive cell growth and proliferation (e.g. JAK2 inhibitor in myeloproliferative syndromes and leukemias), in immunology by regulating the secretion of pro-inflammatory cytokines (e.g. JAK1 inhibitor in chronic lung diseases inflammatory) and in transplantology due to its immunosuppressive effect (inhibition of JAK3 kinase). 

The study was performed with healthy volunteers in two parts: A (single ascending dose) and B (multiple ascending dose), with different doses and placebo control.

Go back

News

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

BioResearch is following  new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic..

Read more …

BRG update on COVID-19

Dear Investigators and Researchers.
In recent days, the whole world is providing heroic fight with the SARS-CoV-2 virus.

Read more …

International Clinical Trials Day

On 28th of June, 2019 we attended the annual conference on the occassion of International Clinical Trials Day titled "On the verge of changes".

Read more …

TransCelerate accreditation

To improve our trainings system, we joined „GCP Mutual Recognition Program" and were accredited by TransCelerate Biopharma Inc

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲